Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
ERJ Open Res ; 9(4)2023 Jul.
Article in English | MEDLINE | ID: mdl-37362883

ABSTRACT

Post-COVID-19 breathing pattern disorder can be characterised by application of nonlinear statistical modelling of exercise ventilatory data https://bit.ly/3WlBc7e.

3.
Pulm Circ ; 13(1): e12201, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36814585

ABSTRACT

Effects of continuous positive airway pressure (CPAP) on right ventricular (RV) function in patients with untreated mild-to-moderate obstructive sleep apnea (OSA) are unclear. In this exploratory analysis of cardiac magnetic resonance (CMR)-derived indices of RV function in patients with minimally symptomatic OSA from the MOSAIC randomized control trial we found no effect of CPAP on RV CMR parameters. In those with lower RV ejection fraction and higher RV end-diastolic volume (EDV) at baseline, CPAP treatment appeared to improve RV function with a significant reduction in both RV EDV and RV end-systolic volume although between-group effects were not observed. These data suggest potential merit in a larger randomized study of CPAP in patients with mild-to-moderate OSA and a greater breadth of RV dysfunction.

4.
Respirology ; 28(3): 262-272, 2023 03.
Article in English | MEDLINE | ID: mdl-36172951

ABSTRACT

BACKGROUND AND OBJECTIVE: Pulmonary hypertension is a life-limiting complication of interstitial lung disease (ILD-PH). We investigated whether treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with ILD-PH was associated with improved survival. METHODS: Consecutive incident patients with ILD-PH and right heart catheterisation, echocardiography and spirometry data were followed from diagnosis to death, transplantation or censoring with all follow-up and survival data modelled by Bayesian methods. RESULTS: The diagnoses in 128 patients were idiopathic pulmonary fibrosis (n = 74, 58%), hypersensitivity pneumonitis (n = 17, 13%), non-specific interstitial pneumonia (n = 12, 9%), undifferentiated ILD (n = 8, 6%) and other lung diseases (n = 17, 13%). Final outcomes were death (n = 106, 83%), transplantation (n = 9, 7%) and censoring (n = 13, 10%). Patients treated with PDE5i (n = 50, 39%) had higher mean pulmonary artery pressure (median 38 mm Hg [interquartile range, IQR: 34, 43] vs. 35 mm Hg [IQR: 31, 38], p = 0.07) and percentage predicted forced vital capacity (FVC; median 57% [IQR: 51, 73] vs. 52% [IQR: 45, 66], p=0.08) though differences did not reach significance. Patients treated with PDE5i survived longer than untreated patients (median 2.18 years [95% CI: 1.43, 3.04] vs. 0.94 years [0.69, 1.51], p = 0.003) independent of all other prognostic markers by Bayesian joint-modelling (HR 0.39, 95% CI: 0.23, 0.59, p < 0.001) and propensity-matched analyses (HR 0.38, 95% CI: 0.22, 0.58, p < 0.001). Survival difference with treatment was significantly larger if right ventricular function was normal, rather than abnormal, at presentation (+2.55 years, 95% CI: -0.03, +3.97 vs. +0.98 years, 95% CI: +0.47, +2.00, p = 0.04). CONCLUSION: PDE5i treatment in ILD-PH should be investigated by a prospective randomized trial.


Subject(s)
Hypertension, Pulmonary , Lung Diseases, Interstitial , Humans , Phosphodiesterase 5 Inhibitors/therapeutic use , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/etiology , Retrospective Studies , Bayes Theorem , Prospective Studies , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/drug therapy
5.
Respir Med ; 200: 106928, 2022.
Article in English | MEDLINE | ID: mdl-35853266

ABSTRACT

BACKGROUND: Accuracy of right heart strain (RHS) measured on computed tomography pulmonary angiogram (CTPA) scans by non-radiologists is unknown. We assessed inter-observer variability of four RHS features and determined the accuracy of measurements by respiratory physicians. METHOD: 1560 consecutive patients with acute PE were identified, and those who had a CTPA and an echocardiogram within 24-h included. CTPAs were independently scored prospectively by two radiologists, two thoracic physicians and a specialist registrar. Inter-observer variability was assessed, and diagnostic accuracy compared to echocardiography. RESULTS: 182 patients (median age 62.8 years, IQR 49.8-71.5) with acute PE (7.7% high-risk, 40.7% intermediate high-risk, 31.3% intermediate low-risk and 20.3% low-risk) were included. Right ventricle to left ventricle diameter ratio (RV:LV) measurement had low inter-observer variability among the radiologists and non-radiologists with interclass correlation coefficient (ICC) of 0.95 (95%CI 0.92-0.97) and 0.96 (95%CI 0.94-0.97) respectively. RV:LV ratio had high diagnostic accuracy compared to RV dilatation on echocardiography (AUC 0.89, 95%CI 0.84-0.94 for radiologists and AUC 0.84, 95%CI 0.77-0.90 for non-radiologists). Main pulmonary artery to ascending aorta diameter ratio (MPA:Ao) measurement also had excellent agreement amongst the radiologists and non-radiologists (ICC 0.93 (95%CI 0.88-0.96) and 0.92 (95%CI 0.81-0.96) respectively). Significant variability was seen in the assessment of subjective features of RHS (leftward bowing of interventricular septum and contrast reflux into inferior vena cava) amongst the non-radiologists. CONCLUSION: RV:LV and MPA:Ao diameter ratios on CTPA measured by non-radiologists have low inter-observer variability and good agreement with radiologists, and can be reliably used where an expert report is unavailable.


Subject(s)
Physicians , Pulmonary Embolism , Humans , Middle Aged , Acute Disease , Angiography/methods , Observer Variation , Pulmonary Embolism/diagnostic imaging , Retrospective Studies
7.
Intern Med J ; 52(2): 272-281, 2022 Feb.
Article in English | MEDLINE | ID: mdl-32896977

ABSTRACT

BACKGROUND: Several recent randomised controlled trials (RCT) have investigated the use of direct oral anticoagulants (DOAC) in the treatment of malignancy-associated venous thromboembolism (VTE). AIMS: This meta-analysis combines all RCT data to determine the risks of recurrent VTE and bleeding with DOAC in patients with malignancy-associated VTE compared with low-molecular-weight heparin (LMWH). METHODS: The study followed PRISMA guidelines. MEDLINE, EMBASE and CENTRAL were systematically searched from inception to 1 April 2020. References of reviews and relevant conference proceedings were searched by hand. Two authors independently evaluated study eligibility, extracted data and assessed risk of bias. Direct and indirect meta-analyses were performed. RESULTS: In four RCT with low risk of bias (2907 patients), high certainty evidence suggested that DOAC had a 37% reduction in risk of recurrent VTE compared with LMWH (direct pooled risk ratio (RR) 0.63; 95% confidence interval (CI) 0.44-0.91; I2 = 28%). No significant difference was observed in the risk of major bleeding with DOAC compared with LMWH (RR 1.31; 95% CI 0.83-2.07; I2 = 22%; moderate certainty evidence), including in patients in gastrointestinal and genitourinary malignancy. An increased risk of combined major or clinically relevant non-major bleeding was seen with DOAC (RR 1.52; 95% CI 1.09-2.12; I2 = 51%; low certainty evidence). Apixaban had the highest probability of being ranked the most effective and least bleeding risk among the DOAC. CONCLUSION: DOAC are effective in treating malignancy associated VTE; however, caution is required in patients with high risk of bleeding. Apixaban had lower risk of bleeding compared to other DOAC in this population.


Subject(s)
Neoplasms , Venous Thromboembolism , Anticoagulants/adverse effects , Heparin/adverse effects , Heparin, Low-Molecular-Weight/adverse effects , Humans , Neoplasms/chemically induced , Neoplasms/complications , Neoplasms/epidemiology , Network Meta-Analysis , Venous Thromboembolism/drug therapy , Venous Thromboembolism/epidemiology
8.
ERJ Open Res ; 7(3)2021 Jul.
Article in English | MEDLINE | ID: mdl-34476251

ABSTRACT

Assessment of efficacy and safety of DOACs in treatment of pulmonary embolisms in obese patients provides reassurance that treatment with DOACs carries similar rates of recurrent VTE and bleeding complications to warfarin https://bit.ly/2VdrSXX.

9.
Int J Cardiol ; 341: 84-87, 2021 Oct 15.
Article in English | MEDLINE | ID: mdl-34416318

ABSTRACT

Studies assessing exercise ventilatory responses during real-life exercise in pulmonary arterial hypertension (PAH) which include patients with cyanotic congenital heart disease are scarce. We assessed the ventilatory response to stairclimbing in patients with idiopathic PAH (IPAH) and congenital heart disease-associated PAH with Eisenmenger (EIS) physiology compared to healthy controls. Fifteen adults with IPAH, six EIS and 15 age and body mass index (BMI) matched controls were prospectively recruited. Participants completed spirometry and a self-paced stair-climb (48 steps) with portable cardiopulmonary exercise testing (CPET) equipment in-situ. Borg dyspnoea scores were measured at rest and on stair-climb cessation. Both IPAH and EIS groups had amplified ventilatory responses compared to Controls. The rate of increase in minute ventilation (VE) was exaggerated in EIS driven by an early increase in tidal volume (Tv) and more gradual increase in respiratory rate (RR). Peak Tv, RR, Tv: forced vital capacity (FVC) ratio, VE/VCO2 slope and stairclimb duration were significantly higher in EIS and IPAH compared to controls despite similar baseline spirometry and change in oxygen uptake on exercise. A decline in end-tidal carbon dioxide (CO2) and arterial oxygen saturations in early exercise distinguished EIS and IPAH patients. Significant correlations were observed between peak exercise Borg score and stair-climb time (r = 0.73, p = 0.002), peak end-tidal CO2 (r = -0.73, p = 0.001), peak VE (r = 0.53, p = 0.008), peak RR (r = 0.42, p = 0.011) and VE/VCO2 slope (r = 0.54, p = 0.001). Patients with IPAH and EIS have exaggerated ventilatory responses to stair-climbing compared to the controls with more severe levels of dyspnoea perception in Eisenmenger syndrome for equivalent oxygen uptake and work.


Subject(s)
Eisenmenger Complex , Adult , Cyanosis , Eisenmenger Complex/diagnosis , Exercise , Exercise Test , Familial Primary Pulmonary Hypertension , Humans , Oxygen Consumption
10.
Curr Opin Pulm Med ; 27(5): 285-295, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34127623

ABSTRACT

PURPOSE OF REVIEW: Sarcoidosis associated pulmonary hypertension (SAPH) is a well-recognised complication, associated with a seven-fold increase in mortality. This comprehensive review will summarise these recent developments and proposes the use of a phenotype-based management approach in SAPH. RECENT FINDINGS: Recent registry-based studies have highlighted the adverse outcomes associated with SAPH and shown that reduced 6-min walk distance and diffusion capacity for carbon monoxide are predictive of poor prognosis. There is increasing interest in methods for early detection of SAPH, although whether early diagnosis impacts on survival remains uncertain. The pathophysiology underpinning SAPH is complex and often incorporates multiple mechanisms. Once the diagnosis is confirmed, understanding the underlying phenotypes of SAPH is key to providing the most effective management plan. There is some evidence that treating patients with precapillary PH with pulmonary vasodilators may improve some haemodynamic and quality life measures. However, more work is needed to determine whether mortality is affected. SUMMARY: SAPH is associated with worsened survival. A range of phenotypes are recognised in SAPH. Multimodality risk assessment in patients with SAPH is likely to be important and is an area that requires further work. Published evidence for pulmonary vasodilator therapies in SAPH with a Pulmonary arterial hypertension-like phenotype is encouraging so far, but multiple confounding factors affects the quality of the evidence. The role of immunosuppressive agents for improving pulmonary pressures is unclear. Urgent controlled trials are needed.


Subject(s)
Hypertension, Pulmonary , Pulmonary Arterial Hypertension , Sarcoidosis, Pulmonary , Sarcoidosis , Humans , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/etiology , Sarcoidosis/drug therapy , Sarcoidosis, Pulmonary/complications , Vasodilator Agents/therapeutic use
12.
ERJ Open Res ; 7(1)2021 Jan.
Article in English | MEDLINE | ID: mdl-33681341

ABSTRACT

This case-control study assessed efficacy and safety of systematic thrombolysis in morbidly obese patients with massive pulmonary embolisms. Thrombolysis at conventional doses seems to have similar efficacy and bleeding rates in morbidly obese patients. https://bit.ly/38ZqJr4.

13.
ERJ Open Res ; 6(1)2020 Jan.
Article in English | MEDLINE | ID: mdl-32166087

ABSTRACT

This study investigated the effects of previous radiation therapy on outcomes from nivolumab in advanced NSCLC, and found that previous radiation therapy resulted in significantly higher survival in patients treated with nivolumab for advanced NSCLC http://bit.ly/3btOFSL.

14.
J Bronchology Interv Pulmonol ; 27(3): 205-211, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32101915

ABSTRACT

BACKGROUND: An optimal sampling sequence in radial guide sheath endobronchial ultrasound lung biopsy (R-EBUS) is unclear. This prospective single-center pilot randomized controlled trial aimed to determine if the initial method and sequence of sampling affect the diagnostic accuracy of the procedure. METHODS: Consecutive patients undergoing R-EBUS for lesions >15 mm with a bronchus sign were randomly assigned (1:1:1) to biopsy first (group A), brushings first (group B) or combination (group C). The primary outcome was a positive diagnosis from any sampling method. RESULTS: Fifty-four patients were randomized. The overall diagnostic yield of the procedure was 77.8% (95% confidence interval: 66%-89%), with no difference between groups. A higher rate of positive cytology from brushings was seen if the biopsies were performed before brushings (77.8% in group A vs. 44.4% in group B, P=0.03). The rate of positive cytology from washings was higher if the washings were obtained just after the brushings (61.1% in group A vs. 11.1% in group B, P=0.02). There was no difference in the rate of positive biopsy histology in the groups (P=0.27). All 3 sampling modalities were more likely to be positive in group A (50.0% vs. 11.1% in group B and 22.2% in group C, P=0.04). Complications rate was low and not significantly different between groups. CONCLUSION: The overall rate of a positive R-EBUS procedure was not affected by the initial sampling method or sequence. However, all 3 sampling modalities were more likely to be positive if biopsies were performed first, followed by brushings and washings.


Subject(s)
Biopsy/instrumentation , Endosonography/methods , Lung Neoplasms/pathology , Lung/pathology , Specimen Handling/methods , Aged , Aged, 80 and over , Bronchi/pathology , Bronchoscopy/methods , Case-Control Studies , Endosonography/instrumentation , Female , Histological Techniques/statistics & numerical data , Humans , Image-Guided Biopsy/methods , Lung Neoplasms/diagnosis , Male , Middle Aged , Prospective Studies , Tomography, X-Ray Computed/methods
15.
Intern Med J ; 50(10): 1253-1258, 2020 Oct.
Article in English | MEDLINE | ID: mdl-31589356

ABSTRACT

BACKGROUND: Respiratory Acute Discharge Service (RADS) is a novel early discharge service with nurse-led community based recovery in selected patients with acute exacerbations of chronic obstructive pulmonary disease. AIM: This pilot study aimed to determine the efficacy and safety of the programme in an Australian tertiary hospital. METHODS: All patients who were recruited to RADS at Sunshine Coast University Hospital over a 6 months period from June to November 2018 were included. The co-primary outcomes were length of hospital days saved and rate of readmission within 30 days from discharge. RESULTS: A total of 166 patients (median age 74 years (interquartile range 70-80 years)) was recruited to the programme over the study period. The mean forced expiratory volume in one second (FEV1%) of the patients was 42% (standard deviation 19). The median length-of-stay prior to discharge on the RADS programme was 1 day (range 0-5), compared to a previous average of 5.8 days in our health service. Patients were on the programme for a median of 4 days (range 1-6). A total of 613 hospital bed days was saved over the study period, with significant cost savings. Forty-one (24.7%) patients represented to hospital within 30 days, the majority (64%) were due to recurrent symptoms. The rate of 30-day all-cause mortality for the study population was 1 (0.6%). CONCLUSION: Early supported discharge care model with nurse-led community based recovery after an acute exacerbation of chronic obstructive pulmonary disease in selected patients is safe, and has the potential to provide greater flow through the hospital systems with cost effective care.


Subject(s)
Patient Discharge , Pulmonary Disease, Chronic Obstructive , Aged , Aged, 80 and over , Australia/epidemiology , Hospitals , Humans , Length of Stay , Pilot Projects , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/therapy
17.
Clin Respir J ; 11(6): 867-874, 2017 Nov.
Article in English | MEDLINE | ID: mdl-26663898

ABSTRACT

BACKGROUND AND OBJECTIVES: Persistent right ventricular dysfunction (RVD) and pulmonary hypertension (PHT) are important outcomes following sub-massive pulmonary embolism (PE). The aims were to determine the rates and factors associated with RVD and/or PHT on echocardiography (ECHO) and the rate of 30-day and 1-year all-cause mortality following sub-massive PE. Patients who received thrombolysis and non-thrombolysis were also compared. METHODS: Consecutive patients with sub-massive PE over a five year period with at least 1-year follow-up were retrospectively identified. Regression analysis was performed to identify predictors of outcomes. RESULTS: Eighty-seven patients met inclusion criteria. Sixty-one (70%) had admission ECHOs with a follow-up ECHO in 42 (48.3%) at a mean of 7.6 months (SD 5.2). Fifty-one had RVD (58.6%) and 35 (40.2%) had PHT on admission. The rates of persistent RVD and raised right ventricular systolic pressure in this study population were 12% and 17%, respectively. Thrombolysis was associated with a trend towards improvement of PHT (53.3% PHT on admission to 0% PHT on follow-up in the thrombolysis group, P = 0.29). The rate of 30-day and 1-year all-cause mortality were 12.6% and 21.8%, respectively. Thirty-day all-cause mortality was independently predicted by the presence of right heart strain on computed tomography pulmonary angiography [OR 3.7 (P = 0.045)], echocardiographic evidence of RVD [OR 3.9 (P = 0.041)] and age. CONCLUSION: The majority of patients with RVD and PHT at the time of sub-massive PE improve on follow-up; however, there is a subset who remain abnormal. Future studies are needed to identify modifiable risk factors for these complications.


Subject(s)
Hypertension, Pulmonary/complications , Pulmonary Embolism/complications , Pulmonary Embolism/epidemiology , Ventricular Dysfunction, Right/complications , Adult , Aged , Aged, 80 and over , Computed Tomography Angiography/methods , Echocardiography , Female , Humans , Hypertension, Pulmonary/diagnostic imaging , Hypertension, Pulmonary/epidemiology , Male , Middle Aged , Mortality , Prognosis , Pulmonary Embolism/mortality , Pulmonary Embolism/therapy , Retrospective Studies , Risk Factors , Thrombolytic Therapy/methods , Ventricular Dysfunction, Right/diagnostic imaging , Ventricular Dysfunction, Right/epidemiology
18.
N Z Med J ; 127(1399): 13-22, 2014 Aug 01.
Article in English | MEDLINE | ID: mdl-25145302

ABSTRACT

AIM: Sleep symptoms, depression and anxiety often coexist and tertiary students are a population group that are increasingly recognised to be at risk. However the rates of these conditions in the New Zealand population are poorly understood. The aim of this study was to determine the rates of sleep disorders, depression and anxiety, and identify correlations between satisfactions with life among university students in Auckland. METHOD: Auckland Sleep Questionnaire (ASQ) was administered to undergraduate students from six schools of The University of Auckland. The different types of sleep disorders were calculated for the students who reported a significant sleep problem lasting more than 1 month. The rate of depression, anxiety and substance use as well as the satisfaction with life scale scores were also calculated for the whole cohort. RESULTS: A total of 1933 students were invited to participate and 66.8% completed the questionnaire. The median age was 20 years (range 16-38) and women represented 63.9% of the total group. A total of 39.4% of the students surveyed reported having significant sleep symptoms lasting longer than 1 month. The most prevalent causes for sleep symptoms were depression and anxiety. Delayed sleep phase disorder was found in 24.9% of students and parasomnias were reported by 12.4%. Depression and anxiety were present in 17.3% and 19.7% of the total group respectively, and 7.3% of students had thoughts of "being better off dead" or self-harm. A total of 15.5% students were found to have a CAGE score greater than or equal to 2 and 9.3% reported using recreational drugs in the last 3 months. Moderate negative correlations between SWLS scores and depression and anxiety were found (r=-0.45 and r=-0.37 respectively). CONCLUSION: A large number of university students are suffering from significant sleep symptoms. Mood disorders, substance use, and circadian rhythm disorders can greatly contribute to sleep difficulties in this population group. The study also showed that harmful alcohol and drug use was common among this population group and is associated with clinically significant depression and anxiety. Accurate diagnosis using defined criteria will enable effective treatment for these conditions that impact greatly on the quality of life.


Subject(s)
Anxiety/epidemiology , Depression/epidemiology , Interpersonal Relations , Sleep Initiation and Maintenance Disorders/epidemiology , Students/statistics & numerical data , Substance-Related Disorders/epidemiology , Adult , Anxiety/psychology , Causality , Cohort Studies , Comorbidity , Depression/psychology , Female , Humans , Incidence , Male , New Zealand/epidemiology , Quality of Life/psychology , Risk Factors , Sleep Initiation and Maintenance Disorders/psychology , Students/psychology , Substance-Related Disorders/psychology , Universities , Young Adult
19.
J Prim Health Care ; 5(4): 276-82, 2013 Dec 01.
Article in English | MEDLINE | ID: mdl-24294615

ABSTRACT

INTRODUCTION: Adolescents are known to have high risk factors for sleep disorders, yet the youth rates of sleep disturbances are unknown. AIM: This study aimed to determine the prevalence of sleep disorders among New Zealand high school students. METHODS: The Auckland Sleep Questionnaire (ASQ) was administered to high school students at six schools in the North Island. Schools were chosen to reflect a range of ethnicities and school deciles, which identify the socioeconomic status of households in the school catchment area. RESULTS: A total of 1388 students completed the ASQ. The median age was 17 years (range 14-23) and females represented 43.5% (n=604) of the total group. A total of 37.2% of the students surveyed reported having significant sleep symptoms lasting longer than one month. Depression and anxiety were present in 51.7% and 44.8% of students reporting a sleep problem, respectively. A moderate correlation was observed between sleep problems and depression (r=0.34, p<0.01), and sleep problems and anxiety (r=0.31, p<0.01). Problem alcohol use and other substance use were more common in students with sleep symptoms (12.2% and 5.5% respectively). No difference was found in the rate of sleep problems reported by different ethnic groups. DISCUSSION: A considerable proportion of students surveyed reported significant sleep symptoms. This study has the potential to aid physicians within New Zealand in better appreciating the burden of sleep disorders faced by young people and in effectively assessing and managing different causes of sleep symptoms in this demographic.


Subject(s)
Sleep Wake Disorders/diagnosis , Students , Adolescent , Female , Humans , Male , New Zealand/epidemiology , Sleep Wake Disorders/epidemiology , Surveys and Questionnaires , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...